Evidence map›Paper›PMID 29122684›Full record

ArticleHuman immunology2018

Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua.

Daniela Weiskopf, Alba Grifoni, Cecilia S Lindestam Arlehamn, Michael Angelo, Shay Leary, John Sidney, April Frazier, Steven J Mack, Elizabeth Phillips, Simon Mallal and 4 more

Abstract read
In one paragraph

Article in Human immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Comprehensive Analysis of CD4Frontiers in immunology · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniela WeiskopfDivision of Vaccine Discovery, La Jolla Institute for Allergy & Immunology (LJI), La Jolla, CA 92037, USA.
Alba GrifoniDivision of Vaccine Discovery, La Jolla Institute for Allergy & Immunology (LJI), La Jolla, CA 92037, USA.
Cecilia S Lindestam ArlehamnDivision of Vaccine Discovery, La Jolla Institute for Allergy & Immunology (LJI), La Jolla, CA 92037, USA.
Michael AngeloDivision of Vaccine Discovery, La Jolla Institute for Allergy & Immunology (LJI), La Jolla, CA 92037, USA.
Shay LearyInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia 6150, Australia.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy & Immunology (LJI), La Jolla, CA 92037, USA. Electronic address: jsidney@lji.org.
April FrazierDivision of Vaccine Discovery, La Jolla Institute for Allergy & Immunology (LJI), La Jolla, CA 92037, USA.
Steven J MackChildren's Hospital Oakland Research Institute, Oakland, CA, USA.
Elizabeth PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia 6150, Australia; Vanderbilt University School of Medicine, Nashville, TN 37235, USA.
Simon MallalInstitute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia 6150, Australia; Vanderbilt University School of Medicine, Nashville, TN 37235, USA.
Cristhiam CerpasLaboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua.
Angel BalmasedaLaboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministerio de Salud, Managua, Nicaragua.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy & Immunology (LJI), La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.

Funding

T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Eva Harris · 2015 to 2026
$34.1M
Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C. · 2015 to 2019
$13.0M
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5M
Integrated Exchange & Storage of Current and Future-Generation Immunogenomic DataR01GM109030 · NIGMS · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI HOLLENBACH, JILL ALLISON, MACK, STEVEN JOHN · 2014 to 2016
$919k
NIAID NIH HHS HHSN272201400045CNIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI128775NIGMS NIH HHS P50 GM115305NIGMS NIH HHS R01 GM109030
6 · The paper itself

Abstract

DNA sequence-based typing at the HLA-A, -B, -C, -DPB1, -DQA1, -DQB1, and -DRB1 loci was performed on anonymized samples provided by 339 healthy adult blood bank donors in Managua, Nicaragua. The purpose of the study was to characterize allele frequencies in the local population to support studies of T cell immunity against pathogens, including Dengue virus. Deviations from Hardy Weinberg proportions were detected for all class II loci (HLA-DPB1, -DQA1, -DQB1 and -DRB1), and at the class I C locus, but not at the class I A and B loci. The genotype data will be available in the Allele Frequencies Net Database.

Indexed as

AdultDatabases, GeneticDengueGene FrequencyGenetics, PopulationGenotypeHistocompatibility TestingHLA-A AntigensHLA-B AntigensHLA-C AntigensHLA-DP AntigensHLA-DQ AntigensHLA-DR AntigensHumansLinkage DisequilibriumNicaraguaHLA-A AntigensHLA-B AntigensHLA-C AntigensHLA-DP AntigensHLA-DQ AntigensHLA-DR AntigensHLA allelesHLA typingManaguaMestizoNicaragua

Identifiers

PMID29122684
PMCPMC5788571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.